Sarclisa Escena (isatuximab-irfc)

Where it stands

The FDA approved Sarclisa Escena (isatuximab-irfc) on 9 July 2026. The sponsor is Sanofi-Aventis U.S. LLC. The records list the status as Approved and give the dosage form as vial. The approval is recorded from an official source.

The records do not give the approved indication, the therapeutic area, or any dosing or administration details. This analysis therefore cannot say which patients the product is approved to treat, or how it is given. The records also do not say how Sarclisa Escena relates to any other isatuximab product, so no comparison or assumption is made here.

Regulatory pathway and designations

The application is BLA761445, a Biologics License Application. The FDA classifies the product as a new biologic. The approval is a single milestone dated 9 July 2026, and the FDA's announcement describes the product as "a new medicine."

The "-irfc" suffix on the nonproprietary name follows the FDA convention of attaching a four-letter suffix to biologic names. The records show no CHMP opinion date, which is expected for a US-region record. They list no expedited-program designations (such as priority review, breakthrough therapy or orphan status), and they give no review timeline or PDUFA goal date. None of these should be inferred.

Safety and pharmacovigilance

The records contain no safety information. They give no boxed warning, contraindications, warnings and precautions, adverse reaction data, or risk management requirements such as a REMS.

In general, a newly approved US biologic is covered by routine pharmacovigilance, including spontaneous adverse event reporting to the FDA, and the label may carry postmarketing requirements or commitments. Whether any apply to this product can only be confirmed from the approved prescribing information and the approval letter, which are not in the records.

What to watch

The first step is to obtain the approved prescribing information and approval letter. These would confirm the indication, dosing, safety language and any postmarketing requirements. They would also show how the product is positioned relative to other products from the same sponsor.

Other points are not covered by the records. These include launch timing, any related filings in other regions such as an EU application and CHMP opinion, and the sponsor's plans. Any assessment of these needs sources beyond the records provided.